Neutropenia Pipeline Analysis report covers 23 drugs currently in different phases of development. Neutropenia means extremely low count of neutrophils in body. Neutrophils are the type of white blood cells and destroy bacteria and other organisms that cause infection. With the lack of neutrophils in the body people with neutropenia are more likely to develop infections. Neutropenia may be congenital or may be acquired as a result of cancer and cancer treatment or due to infections such as Tuberculosis, HIV, viral hepatitis etc. There are no specific symptoms for neutropenia apart from feeling fatigue and a blood test is performed to diagnose the disease. White blood cell growth factors are generally given as treatment to increase the count of neutrophils in the body.
The report provides neutropenia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Shire, IQVIA, Sanofi and Amicus Therapeutics, Inc. among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
* There may be changes in final report as per data availability.